The Use of Diluted Povidone Iodine Irrigation in Spine Surgery

This study is currently recruiting participants.
Verified April 2012 by Attabib, Najmedden, M.D.
Sponsor:
Information provided by (Responsible Party):
Dr. Najmedden Attabib, Attabib, Najmedden, M.D.
ClinicalTrials.gov Identifier:
NCT01577524
First received: March 30, 2012
Last updated: April 12, 2012
Last verified: April 2012

March 30, 2012
April 12, 2012
January 2012
January 2013   (final data collection date for primary outcome measure)
Number of post-operative infections diagnosed in both treatment and control groups [ Time Frame: Twelve months post operation ] [ Designated as safety issue: No ]

The Centers for Disease Control (CDC)definition of surgical site infections (SSI)will be used for this study.This definition addresses both superficial and deep surgical site infections.

Outcome will be determined by the number of superficial, deep, and total (superficial plus deep) wound infections for each group.

Same as current
Complete list of historical versions of study NCT01577524 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Use of Diluted Povidone Iodine Irrigation in Spine Surgery
The Use of Diluted Povidone Iodine Irrigation in Spine Surgery

The purpose of the study is to determine whether diluted Povidone Iodine solution used to irrigate surgical wounds during spine surgery decreases the incidence of surgical site infections.

Post-operative infections in spine surgery have been extensively investigated in the literature. These investigations focus on the efficacy of using peri-operative antibiotics, Povidone Iodine skin preparations, the effects of shaving around the surgical sit, and the use of intra-operative diluted Povidone Iodine wound irrigation in preventing post-operative infections.

Povidone-iodine is a complex of polyvinyl pyrrolidine and tri-iodine ions widely used as an antiseptic agent. It has bactericidal activity against a wide spectrum of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The safety of its use intra-operatively has been evaluated in animal studies and also supported through Randomized Controlled Trials in spinal surgery and in other surgical subspecialties.

The purpose of this study is to evaluate the efficacy of the intra-operative use of diluted Povidone Iodine solution in reducing post-operative infections when used for irrigating surgical incisions during spinal surgery compared with 0.9% Sodium Chloride Irrigation Solution (i.e. normal saline solution).

The primary outcome measure will be seen as a reduction in the number of post-operative infections. As a result and although not directly measured, it is suspected that a reduction in post-operative infections may result in quicker healing with fewer complications and pain.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Surgical Site Infection
  • Drug: Povidone-Iodine
    Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
    Other Name: Betadine
  • Drug: Saline
    Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
  • Active Comparator: Diluted Povidone Iodine Solution
    Intervention: Drug: Povidone-Iodine
  • Placebo Comparator: Normal Saline Wash
    Intervention: Drug: Saline

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
430
June 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age of 18-75
  • Undergoing posterior surgical spinal procedure for degenerative spine disease, extra-dural tumors, trauma, or spinal deformity
  • No obvious potential infective focus
  • Patient willing to enroll

Exclusion Criteria:

  • Age <18 or >75
  • Identified infective focus in the body, including furuncles,or acne at surgical incision site
  • Patient with discitis or spinal osteomyelitis
  • Dural tear
  • Potential use of Bone Morphogenic Protein (BMP)
  • Iodine hypersensitivity
  • Out of province patients due to difficulty in arranging follow up visits
  • Minimal invasive spine surgical procedure (MISS) due to difficulty of having diluted Betadine solution contact soft tissue with the use if MISS retractors
  • Pregnancy
  • Inability to provide informed consent
Both
18 Years to 75 Years
No
Contact: Heidi Kelly, BN 506-648-6373 heidi.kelly@horizonNB.ca
Contact: Najmedden Attabib, MD 506-648-7160 attabib2002@yahoo.com
Canada
 
NCT01577524
2009-1350
No
Dr. Najmedden Attabib, Attabib, Najmedden, M.D.
Attabib, Najmedden, M.D.
Not Provided
Principal Investigator: Najmedden Attabib, MD Neurosurgery Department, Saint John Regional Hospital
Attabib, Najmedden, M.D.
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP